Compare ACR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | CRBU |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 138.3M |
| IPO Year | 2005 | 2021 |
| Metric | ACR | CRBU |
|---|---|---|
| Price | $9.97 | $0.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 53.7K | ★ 4.1M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,946,000.00 | N/A |
| Revenue This Year | N/A | $145.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.92 | $0.44 |
| 52 Week High | $24.61 | $3.53 |
| Indicator | ACR | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 12.76 |
| Support Level | $9.92 | N/A |
| Resistance Level | $14.97 | $1.73 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 4.99 | 1.55 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.